ARCH Venture Fund XII, L.P.
Insider CIK 1906837 · NMRA 10% owner · PRME 10% owner · RAPP 10% owner · MTSR Director, 10% owner · SPTX 10% owner · CTY 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| CTY CITY THERAPEUTICS, INC. | C Conversion deriv | 2026-10-19 | 2026-10-19 | 1,845,585 | — | $0 | 0 | SEC↗ |
| CTY CITY THERAPEUTICS, INC. | C Conversion deriv | 2026-10-19 | 2026-10-19 | 4,991,633 | — | $0 | 0 | SEC↗ |
| CTY CITY THERAPEUTICS, INC. | C Conversion deriv | 2026-10-19 | 2026-10-19 | 3,000,000 | — | $0 | 0 | SEC↗ |
| CTY CITY THERAPEUTICS, INC. | P Buy | 2026-10-19 | 2026-10-19 | 170,000 | $18.00 | $3.06M | 13,692,507 | SEC↗ |
| CTY CITY THERAPEUTICS, INC. | C Conversion | 2026-10-19 | 2026-10-19 | 2,027,006 | — | — | 13,522,507 | SEC↗ |
| CTY CITY THERAPEUTICS, INC. | C Conversion | 2026-10-19 | 2026-10-19 | 5,482,309 | — | — | 11,495,501 | SEC↗ |
| CTY CITY THERAPEUTICS, INC. | C Conversion | 2026-10-19 | 2026-10-19 | 3,294,900 | — | — | 6,013,192 | SEC↗ |
| SPTX Seaport Therapeutics, Inc. | C Conversion deriv | 2026-05-04 | 2026-05-04 | 2,513,686 | — | $0 | 0 | SEC↗ |
| SPTX Seaport Therapeutics, Inc. | C Conversion deriv | 2026-05-04 | 2026-05-04 | 2,681,265 | — | $0 | 0 | SEC↗ |
| SPTX Seaport Therapeutics, Inc. | C Conversion | 2026-05-04 | 2026-05-04 | 2,513,686 | — | $0 | 2,513,686 | SEC↗ |
| SPTX Seaport Therapeutics, Inc. | C Conversion | 2026-05-04 | 2026-05-04 | 2,681,265 | — | $0 | 5,194,951 | SEC↗ |
| SPTX Seaport Therapeutics, Inc. | P Buy | 2026-05-04 | 2026-05-04 | 1,100,000 | $18.00 | $19.80M | 6,294,951 | SEC↗ |
| MTSR Metsera, Inc. | D To issuer | 2025-11-13 | 2025-11-14 | 18,503,128 | — | $0 | 0 | SEC↗ |
| MTSR Metsera, Inc. | D To issuer | 2025-11-13 | 2025-11-14 | 8,313,680 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2025-10-27 | 2025-10-29 | 1,915,700 | $2.61 | $5.00M | 6,046,907 | SEC↗ |
| PRME Prime Medicine, Inc. | P Buy | 2025-08-01 | 2025-08-01 | 3,030,300 | $3.30 | $10.00M | 6,230,300 | SEC↗ |
| MTSR Metsera, Inc. | C Conversion deriv | 2025-02-03 | 2025-02-03 | 19,933,333 | — | $0 | 0 | SEC↗ |
| MTSR Metsera, Inc. | C Conversion deriv | 2025-02-03 | 2025-02-03 | 15,000,000 | — | $0 | 0 | SEC↗ |
| MTSR Metsera, Inc. | C Conversion deriv | 2025-02-03 | 2025-02-03 | 2,678,571 | — | $0 | 0 | SEC↗ |
| MTSR Metsera, Inc. | C Conversion deriv | 2025-02-03 | 2025-02-03 | 15,000,000 | — | $0 | 0 | SEC↗ |
| MTSR Metsera, Inc. | C Conversion deriv | 2025-02-03 | 2025-02-03 | 2,678,571 | — | $0 | 0 | SEC↗ |
| MTSR Metsera, Inc. | C Conversion | 2025-02-03 | 2025-02-03 | 7,523,682 | — | $0 | 7,523,682 | SEC↗ |
| MTSR Metsera, Inc. | P Buy | 2025-02-03 | 2025-02-03 | 1,432,224 | $18.00 | $25.78M | 18,503,128 | SEC↗ |
| MTSR Metsera, Inc. | P Buy | 2025-02-03 | 2025-02-03 | 789,998 | $18.00 | $14.22M | 8,313,680 | SEC↗ |
| MTSR Metsera, Inc. | C Conversion | 2025-02-03 | 2025-02-03 | 16,006,949 | — | $0 | 17,070,904 | SEC↗ |
| RAPP Rapport Therapeutics, Inc. | C Conversion deriv | 2024-06-10 | 2024-06-10 | 20,000,000 | — | $0 | 0 | SEC↗ |
| RAPP Rapport Therapeutics, Inc. | C Conversion deriv | 2024-06-10 | 2024-06-10 | 11,924,138 | — | $0 | 0 | SEC↗ |
| RAPP Rapport Therapeutics, Inc. | C Conversion | 2024-06-10 | 2024-06-10 | 3,728,738 | — | $0 | 3,728,738 | SEC↗ |
| PRME Prime Medicine, Inc. | P Buy | 2024-02-15 | 2024-02-20 | 3,200,000 | $6.25 | $20.00M | 3,200,000 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | J Other | 2023-12-08 | 2023-12-12 | 1,176,593 | — | $0 | 2,321,566 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | J Other | 2023-12-08 | 2023-12-12 | 703,061 | — | $0 | 1,387,228 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-11-14 | 2023-11-15 | 3,357 | $11.98 | $40.2K | 4,131,207 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-11-13 | 2023-11-15 | 31,653 | $11.75 | $371.9K | 4,127,850 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-11-10 | 2023-11-13 | 5,431 | $11.75 | $63.8K | 4,096,197 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-11-10 | 2023-11-13 | 11,844 | $11.37 | $134.7K | 4,090,766 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-11-09 | 2023-11-13 | 31,079 | $10.53 | $327.3K | 4,078,922 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-11-08 | 2023-11-13 | 69,127 | $10.78 | $745.2K | 4,024,719 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-11-08 | 2023-11-13 | 23,124 | $11.79 | $272.6K | 4,047,843 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-11-07 | 2023-11-07 | 30,192 | $11.50 | $347.2K | 3,955,592 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-11-06 | 2023-11-07 | 43,082 | $11.55 | $497.6K | 3,925,400 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-11-03 | 2023-11-07 | 22,420 | $11.38 | $255.1K | 3,882,318 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-09-29 | 2023-09-29 | 34,560 | $13.98 | $483.1K | 3,859,898 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-09-28 | 2023-09-29 | 25,110 | $13.69 | $343.8K | 3,825,338 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-09-28 | 2023-09-29 | 16,841 | $13.06 | $219.9K | 3,800,228 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-09-27 | 2023-09-27 | 24,504 | $12.31 | $301.6K | 3,783,387 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-09-26 | 2023-09-27 | 34,000 | $11.73 | $398.8K | 3,758,883 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-09-25 | 2023-09-25 | 29,967 | $11.65 | $349.1K | 3,724,883 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-09-25 | 2023-09-25 | 30,773 | $10.80 | $332.3K | 3,694,916 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-09-22 | 2023-09-25 | 40,000 | $11.14 | $445.6K | 3,664,143 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-20 | 2,124,143 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-20 | 684,167 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-20 | 1,144,973 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-20 | 6,895,021 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-20 | 6,576,400 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | P Buy | 2023-09-19 | 2023-09-20 | 1,500,000 | $17.00 | $25.50M | 3,624,143 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion | 2023-09-19 | 2023-09-20 | 684,167 | — | $0 | 684,167 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion | 2023-09-19 | 2023-09-20 | 1,144,973 | — | $0 | 1,144,973 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion | 2023-09-19 | 2023-09-20 | 6,895,021 | — | $0 | 12,205,379 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion | 2023-09-19 | 2023-09-20 | 2,124,143 | — | $0 | 2,124,143 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | C Conversion | 2023-09-19 | 2023-09-20 | 6,576,400 | — | $0 | 11,886,758 | SEC↗ |